Business context and reporting period
The supplied filing is Arsanis, Inc.’s Form 10-K for the fiscal year ended December 31, 2018, filed March 11, 2019—not a 10-K filed under X4 Pharmaceuticals’ name. Arsanis was a clinical-stage biopharmaceutical company with no approved products or product-sales revenue. Its lead program, ASN100, targeted Staphylococcus aureus pneumonia; ASN500, an RSV antibody, remained preclinical.
Arsanis had agreed to merge with X4 Pharmaceuticals in November 2018. The merger was pending at filing, and completion and expected benefits were not assured. If completed, X4 shareholders were expected to own approximately 68.1% of the combined company on a fully diluted basis.
Financial results and liquidity
| Metric | 2018 | 2017 |
|---|---|---|
| Revenue | $3.5 million | None |
| Research and development expense | $31.0 million | $28.1 million |
| General and administrative expense | $18.4 million | $8.0 million |
| Operating loss | $45.9 million | $36.1 million |
| Net loss | $43.0 million | $33.9 million |
| Net loss per share | $3.01 | $16.45 |
| Cash used in operating activities | $40.9 million | $27.9 million |
| Cash and cash equivalents at year-end | $30.8 million | $76.8 million |
| Working capital | $29.7 million | $68.9 million |
2018 revenue was a one-time $3.5 million license fee from Janssen for a non-exclusive license to specified ASN200-related patents; no product sales occurred. The filing does not provide a meaningful product gross margin, and operating margins are not informative for this pre-revenue development company. Interest expense was $1.0 million; grant and incentive income was $3.2 million.
Cash, cash equivalents and restricted cash totaled $31.4 million at year-end. The company reported $9.7 million of FFG loan principal outstanding; the balance-sheet carrying value was $7.9 million net of discount. It repaid its remaining Silicon Valley Bank loan obligations in October 2018. Management estimated available cash would fund operating expenses, capital needs and debt service through Q4 2020 under its then-current plan. The auditor highlighted that additional financing would be required for planned future operations.
For Q4 2018, revenue was $3.5 million, operating expenses were $13.0 million and net loss was $9.4 million, or $0.65 per share. The filing provides no quarterly cash-flow or margin figures.
Material changes versus prior comparable period
- Revenue increased from zero to $3.5 million, solely from the Janssen license.
- Net loss widened by $9.1 million, while operating cash use increased by $13.0 million.
- G&A expense rose $10.4 million, primarily reflecting public-company costs, higher stock-based compensation and severance and retention costs. R&D expense increased $2.9 million.
- Cash and cash equivalents fell by $46.0 million. The company used $40.9 million in operating activities and $4.5 million in financing activities, including repayment of SVB debt.
- ASN100 Phase 2 was discontinued after an interim futility review. In the final analysis, pneumonia occurred in 5 of 76 ASN100 patients (6.6%) and 7 of 76 placebo patients (9.2%); the difference was not statistically significant and the primary endpoint was not achieved.
Outlook, risks and unusual items
- ASN500 was in preclinical development; the company said Phase 1 trials were expected to begin in the first half of 2020. ASN200 and ASN300 were outlicensed to Bravos subsidiaries. Arsanis was seeking collaboration or out-licensing opportunities for ASN100 and was evaluating strategic alternatives.
- Arsanis eliminated 28 positions, approximately 65% of its workforce, through March 1, 2019. It estimated total severance and retention costs of $5.9 million, including $2.4 million expected in Q1 2019.
- After year-end, FFG demanded repayment of approximately €18.1 million, including grants, loan principal and assessed interest. Under a March 8, 2019 settlement, FFG waived grant-repayment and excess-interest claims subject to compliance; Arsanis GmbH agreed to repay €8.5 million of loan principal plus regular interest on an accelerated schedule, including a €2.6 million 2019 payment. The settlement also requires minimum cash reserves at the Austrian subsidiary, at least eight full-time-equivalent employees and specified Austrian premises and IP conditions through 2021. Breach could accelerate repayment.
- The merger remained conditional. Failure to close could lead the board to consider liquidation; cash available to stockholders would depend on remaining cash and reserves for obligations. The filing also cited merger-related dilution, execution and financing risks.
- Other key risks include continued losses and dependence on additional capital, clinical and regulatory failure, manufacturing and third-party dependence, competition, intellectual-property and licensing obligations, and possible limits on use of tax attributes following an ownership change.
- Arsanis reported effective disclosure controls and internal control over financial reporting at December 31, 2018. The financial statements received an unqualified audit opinion; the auditor did not opine on internal-control effectiveness.
Important facts for investors to verify
- Whether the X4 merger closed, its final exchange ratios and ownership dilution, and the actual net cash delivered at closing.
- Compliance with the FFG settlement, including the €2.6 million 2019 payment, restricted minimum cash and Austrian operating requirements.
- Actual cash burn and runway after the workforce reduction, severance payments, merger costs and debt repayments.
- ASN500 development progress, the timing and funding of clinical entry, and any partner or licensing arrangements for ASN100, ASN200 or ASN300.
- The terms and continuing obligations of Janssen, Adimab and Gates Foundation agreements, including any contingent payments, royalties, access rights or restrictions.